Clinical Research Directory

Long-Term Health Effects of Previous COVID-19 in Patients Undergoing Preoperative Anesthesia Evaluation

The COVID-19 pandemic has resulted in persistent health problems in a significant proportion of individuals after recovery from the acute infection. These long-term manifestations, commonly referred to as post-COVID condition or long COVID, may involve respiratory, cardiovascular, neurological, psychological, and general health domains. Understanding these sequelae is particularly important in patients undergoing preoperative anesthesia evaluation, as residual symptoms may influence perioperative risk assessment and clinical decision-making. This cross-sectional observational study aims to evaluate the long-term clinical and health effects of previous COVID-19 infection in adult patients presenting to the preoperative anesthesia clinic. Patients aged 18 years and older who report a history of confirmed COVID-19 infection will be included. Clinical data related to the acute infection period (disease severity, hospitalization, intensive care unit admission, oxygen therapy, and radiological findings) will be retrospectively obtained from hospital records. At the time of preoperative assessment, participants will complete a structured post-COVID clinical questionnaire to evaluate persistent symptoms across multiple organ systems. The study seeks to determine the prevalence and characteristics of long-term post-COVID symptoms and to explore potential associations between acute disease severity and ongoing health complaints. No additional medical intervention will be performed as part of this research.

Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID

The primary purpose of this phase 2a study is to compare the efficacy of abrocitinib to placebo in improving severe fatigue in non-hospitalized adults with symptomatic Post-COVID Condition (PCC) (also called Long COVID). We are also interested in learning if abrocitinib is effective in improving overall health status in people suffering from severe fatigue from PCC. Eligible participants with a confirmed history of COVID19 infection who also have PCC according to the World Health Organization definition, will be randomized to receive abrocitinib at a dose of 50 mg, 100 mg, or placebo by mouth daily for 12 weeks (84 days).

A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition

REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.

Effects of Hydrotherapy During Post-COVID-19 Rehabilitation

This randomized controlled study evaluates the effects of cold water hydrotherapy as an adjunct to standard rehabilitation in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to standard rehabilitation alone.

Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial

Long COVID is a complex condition that affects approximately 1.4 million Canadians following SARS-CoV-2 infection. Fatigue is the most common symptom of Long COVID. This feasibility trial will evaluate a new rehabilitation program called COVIDEx for treating fatigue after COVID-19, and compare its effectiveness to the standard treatment currently used. The experimental treatment group will receive an 8-week multi-modal rehabilitation program with two 50-minute sessions per week. 60 participants will be recruited, randomly assigned to the COVIDEx program or standard of care (SoC) and followed for 24 weeks.

Munich Long COVID Registry for Children, Adolescents, and Adults

The MLC-R aims to create a large-scale registry that provides data on epidemiology, phenotypes, and disease trajectories of and health care for Long COVID at any age in Germany, which can be used for future clinical trials.